{"id":5731,"date":"2016-11-10T13:07:00","date_gmt":"2016-11-10T13:07:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/what-is-truthful-and-non-misleading\/"},"modified":"2019-02-21T01:14:50","modified_gmt":"2019-02-21T01:14:50","slug":"what-is-truthful-and-non-misleading","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/","title":{"rendered":"What is “Truthful and Non-misleading?” That is the Question FDA Must Answer to Allow Off-Label Communications by Pharma"},"content":{"rendered":"

Yesterday, I attended and presented at FDA’s Public Hearing<\/a> on drug company communications regarding unapproved uses of drugs. My presentation had to do with off-label promotion directed at consumers and patients (find it here<\/a> on Slideshare).<\/p>\n

Just a few takeaways.<\/p>\n

The phrase “truthful and non-misleading” was mentioned several times during the meeting, including by PhRMA (read “BIO #Pharma Industry Offers Its Own Set of Off-Label Communications Principles<\/a>“) and the Washington Legal Foundation (WLF).<\/p>\n

In its testimony (here<\/a>), the WLF said:<\/p>\n

\n“Starting in the late 1990s with the Washington Legal Foundation cases, courts have consistently
\nupheld corporations\u2019 and their representatives\u2019 First Amendment rights to communicate
\ntruthfully and non-misleadingly about the effects of their products. Courts have held that such a
\nright is not limited by FDA approval of the use that is under discussion. Rather, the limiting
\nfactor on a company\u2019s speech is a classic First Amendment test: whether the communication is
\nfalse or misleading. Therefore, the FDA may only restrict health care companies\u2019 speech
\nregarding both approved and off-label uses if it is untrue or misleading to the listener. This test
\nis grounded in both the Constitution and sound public policy. Pharmaceutical and medical
\ndevice companies and their representatives possess the same rights to free speech under the First
\nAmendment as other individuals, and patient care is strengthened by increased access to truthful
\ninformation and innovation regardless of its origins.” <\/p>\n

But defining what is true and non-misleading is difficult as many presenters noted.<\/p>\n

<\/a>Something can be truthful but also misleading as pointed out by Dr. Aaron Kesselheim, Associate Professor of Medicine, Harvard Medical School\/Brigham and Women’s Hospital.<\/p>\n

Dr. Kesselheim used the Amarin off-label court case as an example. Kesselheim said that Amarin\u2019s argument was \u201cfaulty, because the so-called \u2018truthful and non-misleading\u2019 statement is a tautology.\u201d Amarin was telling doctors this about its fish oil product:<\/p>\n

\n\u201cSupportive but not conclusive research shows that consumption of EPA [acid eicosapentaenoic acid] and DHA [docosahexaenoic acid] omega-3 fatty acids may reduce the risk of coronary heart disease.\u201d<\/p>\n

The CHD benefit is not part of the official, FDA-approved labeling for the drug.<\/p>\n

\u201cAll this qualification really \u2018says\u2019 is that non-conclusive research has been conducted, but then the second half of the claim expresses nothing at all about the clinical import of that research,\u201d said Kesselheim who illustrated the problem by slightly rewording Amarin’s statement so it would NOT be misleading:<\/p>\n

\n\u201cSupportive but not conclusive research shows that consumption of EPA [acid eicosapentaenoic acid] and DHA [docosahexaenoic acid] omega-3 fatty acids may or may not<\/b> reduce the risk of coronary heart disease.\u201d<\/p>\n

For more on this read “Harvard Professors Diss Off-Label #Pharma Free Speech as Non-Scientific<\/a>“).<\/p>\n

\nThere were other seemingly simple terms that presenters wanted the FDA to better define. For example, what does FDA mean by “advertising?”<\/p>\n

Zoe Dunn of Hale Advisors was in favor of Direct-to-Consumer (DTC) off-label “communications” as long as they were not “Promotional.” But where is the bright red line between promotional and non-promotional when a for-profit drug company is communicating with potential users of its products?<\/p>\n

I’ll publish a more detailed synopsis of presentations made at this meeting in a few days. Meanwhile, here is the Twitter #FDAofflabel timeline, which is focused on the the hearing and the issue of off-label drug promotion:<\/p>\n

#FDAofflabel Tweets<\/a>
\n!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=\/^http:\/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+”:\/\/platform.twitter.com\/widgets.js”;fjs.parentNode.insertBefore(js,fjs);}}(document,”script”,”twitter-wjs”);<\/p>\n","protected":false},"excerpt":{"rendered":"

Yesterday, I attended and presented at FDA’s Public Hearing on drug company communications regarding unapproved uses of drugs. My presentation had to do with off-label promotion directed at consumers and patients (find it here on Slideshare). Just a few takeaways. The phrase “truthful and non-misleading” was mentioned several times during the meeting, including by PhRMA […]<\/p>\n","protected":false},"author":2,"featured_media":13101,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12],"tags":[44,139],"topic":[],"acf":[],"yoast_head":"\nWhat is "Truthful and Non-misleading?" That is the Question FDA Must Answer to Allow Off-Label Communications by Pharma - Pharma Marketing Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"What is "Truthful and Non-misleading?" That is the Question FDA Must Answer to Allow Off-Label Communications by Pharma - Pharma Marketing Network\" \/>\n<meta property=\"og:description\" content=\"Yesterday, I attended and presented at FDA’s Public Hearing on drug company communications regarding unapproved uses of drugs. My presentation had to do with off-label promotion directed at consumers and patients (find it here on Slideshare). Just a few takeaways. The phrase “truthful and non-misleading” was mentioned several times during the meeting, including by PhRMA […]\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Marketing Network\" \/>\n<meta property=\"article:published_time\" content=\"2016-11-10T13:07:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-21T01:14:50+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2019\/03\/pmn-logo-intro-post-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"744\" \/>\n\t<meta property=\"og:image:height\" content=\"419\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pharma Guy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pharma Guy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/\",\"name\":\"What is \\\"Truthful and Non-misleading?\\\" That is the Question FDA Must Answer to Allow Off-Label Communications by Pharma - Pharma Marketing Network\",\"isPartOf\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\"},\"datePublished\":\"2016-11-10T13:07:00+00:00\",\"dateModified\":\"2019-02-21T01:14:50+00:00\",\"author\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\"},\"breadcrumb\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"What is “Truthful and Non-misleading?” That is the Question FDA Must Answer to Allow Off-Label Communications by Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\",\"name\":\"Pharma Marketing Network\",\"description\":\"Pharma Marketing Network\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\",\"name\":\"Pharma Guy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/\",\"url\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"contentUrl\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"caption\":\"Pharma Guy\"},\"description\":\"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"What is \"Truthful and Non-misleading?\" That is the Question FDA Must Answer to Allow Off-Label Communications by Pharma - Pharma Marketing Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/","og_locale":"en_US","og_type":"article","og_title":"What is \"Truthful and Non-misleading?\" That is the Question FDA Must Answer to Allow Off-Label Communications by Pharma - Pharma Marketing Network","og_description":"Yesterday, I attended and presented at FDA’s Public Hearing on drug company communications regarding unapproved uses of drugs. My presentation had to do with off-label promotion directed at consumers and patients (find it here on Slideshare). Just a few takeaways. The phrase “truthful and non-misleading” was mentioned several times during the meeting, including by PhRMA […]","og_url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/","og_site_name":"Pharma Marketing Network","article_published_time":"2016-11-10T13:07:00+00:00","article_modified_time":"2019-02-21T01:14:50+00:00","og_image":[{"width":744,"height":419,"url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2019\/03\/pmn-logo-intro-post-1.jpg","type":"image\/jpeg"}],"author":"Pharma Guy","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pharma Guy","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/","name":"What is \"Truthful and Non-misleading?\" That is the Question FDA Must Answer to Allow Off-Label Communications by Pharma - Pharma Marketing Network","isPartOf":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website"},"datePublished":"2016-11-10T13:07:00+00:00","dateModified":"2019-02-21T01:14:50+00:00","author":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1"},"breadcrumb":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/what-is-truthful-and-non-misleading\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/"},{"@type":"ListItem","position":2,"name":"What is “Truthful and Non-misleading?” That is the Question FDA Must Answer to Allow Off-Label Communications by Pharma"}]},{"@type":"WebSite","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/","name":"Pharma Marketing Network","description":"Pharma Marketing Network","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1","name":"Pharma Guy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/","url":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","contentUrl":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","caption":"Pharma Guy"},"description":"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/"}]}},"_links":{"self":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/5731"}],"collection":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/comments?post=5731"}],"version-history":[{"count":1,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/5731\/revisions"}],"predecessor-version":[{"id":12254,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/5731\/revisions\/12254"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media\/13101"}],"wp:attachment":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media?parent=5731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/categories?post=5731"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/tags?post=5731"},{"taxonomy":"topic","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/topic?post=5731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}